The quantification of MC provides a surrogate for monitoring the size of the population of malignant cells in patients affected by plasma cell disease (PCD). Consequently, clinical and laboratory guidelines on diagnosis, risk stratification and monitoring of PCD recommend MC quantification as a key information for patient management. To do that, liquid phase immunochemical determination of IgG, IgA and IgM in serum should not be used, because of the inability of the technique to distinguish between monoclonal and polyclonal immunoglobulins. However, new available immunoassays specifically measuring free light chains, or the "so-called" Hevylite assay, may reliably quantify specific MC. As a general recommendation, MC should be quantified on agarose gel electrophoresis by scanning densitometry or from capillary zone electrophoresis readout only, provided that a high resolution electrophoresis is performed and a low concentration MC obscured by other proteins is not present. For integration of the MC peak on electrophoresis, perpendicular drop method is recommended. MC is a critical "analyte" as the potential analytical pitfalls (detection limit depending on the position of the MC and on the polyclonal background, poor linearity of scanning methods, precision performance) show. Thus, a comprehensive program of IQC of MC quantification should be implemented as well as an EQAS.

Indicazioni per la quantificazione delle componenti monoclonali nel siero = Recommendations for the quantification of serum monoclonal components (MC) / A. Vernocchi, A. Dolci, F. Ceriotti, G. Lippi, G. Merlini, M. Graziani, A. Caldini, M. Mussap, P. Natali, G. Patelli, S. Maoggi, G. Righetti, A. Lalli. - In: BIOCHIMICA CLINICA. - ISSN 0393-0564. - 39:3(2015), pp. 199-207.

Indicazioni per la quantificazione delle componenti monoclonali nel siero = Recommendations for the quantification of serum monoclonal components (MC)

A. Dolci;
2015

Abstract

The quantification of MC provides a surrogate for monitoring the size of the population of malignant cells in patients affected by plasma cell disease (PCD). Consequently, clinical and laboratory guidelines on diagnosis, risk stratification and monitoring of PCD recommend MC quantification as a key information for patient management. To do that, liquid phase immunochemical determination of IgG, IgA and IgM in serum should not be used, because of the inability of the technique to distinguish between monoclonal and polyclonal immunoglobulins. However, new available immunoassays specifically measuring free light chains, or the "so-called" Hevylite assay, may reliably quantify specific MC. As a general recommendation, MC should be quantified on agarose gel electrophoresis by scanning densitometry or from capillary zone electrophoresis readout only, provided that a high resolution electrophoresis is performed and a low concentration MC obscured by other proteins is not present. For integration of the MC peak on electrophoresis, perpendicular drop method is recommended. MC is a critical "analyte" as the potential analytical pitfalls (detection limit depending on the position of the MC and on the polyclonal background, poor linearity of scanning methods, precision performance) show. Thus, a comprehensive program of IQC of MC quantification should be implemented as well as an EQAS.
Settore BIO/12 - Biochimica Clinica e Biologia Molecolare Clinica
2015
https://www.sibioc.it/bc/numero/bcnum/152
Article (author)
File in questo prodotto:
File Dimensione Formato  
2015 BC Dolci A. Documento quantificazione CM.pdf

accesso aperto

Dimensione 525.26 kB
Formato Adobe PDF
525.26 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/702592
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 5
social impact